{"gene":"CYP1A2","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":1984,"finding":"Mouse cytochrome P3-450 (CYP1A2 ortholog) cDNA was fully sequenced, revealing a 513-residue protein with six cysteine residues; analysis of cysteinyl peptide-coding regions identified cysteine 456 as the likely thiolate ligand to the heme iron in the active site.","method":"cDNA cloning and sequencing; sequence homology analysis of cysteinyl peptide-coding regions","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — sequence-based identification of active-site cysteine, single study, no mutagenesis validation in this paper","pmids":["6324134"],"is_preprint":false},{"year":1984,"finding":"Mouse Cyp1a1 and Cyp1a2 (P1-450 and P3-450) structural genes were mapped to mouse chromosome 9 by Southern blot analysis of hamster-mouse somatic cell hybrids.","method":"Somatic cell hybrid Southern blot chromosome segregation analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct chromosomal mapping with 12 hybrid clones, clear segregation analysis","pmids":["6328503"],"is_preprint":false},{"year":1988,"finding":"CYP1A2 (cytochrome P3-450) cDNA encodes aflatoxin B1-4-hydroxylase activity, establishing CYP1A2 as the enzyme responsible for detoxification of AFB1 to aflatoxin M1; demonstrated by expression in mammalian cells via recombinant vaccinia virus.","method":"Recombinant vaccinia virus expression system; in vitro metabolic assay with AFB1 substrate","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct enzymatic reconstitution using cDNA-expressed protein, clear substrate-product demonstration","pmids":["3137222"],"is_preprint":false},{"year":1993,"finding":"CYP1A2 protein is highly variably expressed in human liver (>40-fold variation in mRNA); hepatic CYP1A2 mRNA levels significantly correlate with CYP1A2 protein levels by immunoblot. An abnormally spliced variant lacking exon 4 was identified in one individual with very low CYP1A2 protein, suggesting aberrant splicing as one mechanism of reduced expression.","method":"Quantitative PCR; immunoblot; cDNA cloning and sequencing; PCR splice variant analysis","journal":"Pharmacogenetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (qPCR, immunoblot, sequencing) in single study; mechanistic link between splicing defect and low expression established","pmids":["8287062"],"is_preprint":false},{"year":1993,"finding":"Mouse CYP1A2 preferentially catalyzes MROD (7-methoxyresorufin O-demethylase) activity, while CYP1A1 preferentially catalyzes benzo[a]pyrene hydroxylase and EROD activities; furafylline is a CYP1A2-selective inhibitor of MROD and EROD, whereas alpha-naphthoflavone equally inhibits AHH activity of CYP1A1 and CYP1A2.","method":"Vaccinia virus cDNA expression system; enzyme kinetics (kcat, Km); selective chemical inhibition; immunoblot","journal":"Archives of biochemistry and biophysics","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted expressed enzyme with full kinetic characterization and isoform-specific inhibitors, replicated across microsomal and purified enzyme preparations","pmids":["8274012"],"is_preprint":false},{"year":1994,"finding":"Human CYP1A2 (constitutively expressed in liver) is the primary enzyme responsible for N-hydroxylation and metabolic activation of heterocyclic amines IQ and MeIQx to mutagens; PhIP activation is shared with CYP1A1. This was established by correlation of CYP1A2 constitutive expression with activation rates in human and primate liver microsomes and by TCDD-induced CYP1A2 induction in marmoset with proportional increases in IQ and MeIQx activation.","method":"Human/primate liver microsomal incubations; Ames mutagenicity assay; correlation of CYP levels with activation rates; TCDD induction experiments","journal":"Carcinogenesis","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple species, correlation and induction experiments, clear substrate-enzyme relationship established","pmids":["8200083"],"is_preprint":false},{"year":1996,"finding":"CYP1A2-deficient (Cyp1a2−/−) mice develop normally and are fertile, but exhibit dramatically prolonged zoxazolamine-induced paralysis (a CYP1A2 substrate), demonstrating that CYP1A2 is required for in vivo metabolism of this substrate. Cyp1a2(+/−) heterozygotes show intermediate paralysis times.","method":"Homologous recombination knockout mouse; zoxazolamine paralysis test; Northern blot; histological examination","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with clear dose-dependent phenotypic readout, Northern blot confirmation of null expression","pmids":["8643688"],"is_preprint":false},{"year":1996,"finding":"CYP1A2 is the primary determinant of caffeine clearance in mice: Cyp1a2−/− mice show 7-fold longer caffeine half-life and 8-fold slower clearance compared to wild-type. Caffeine 3-demethylated metabolites (1-methylxanthine, 1-methylurate) are still formed in Cyp1a2−/− mice at 40% of wild-type levels, indicating additional P450s contribute.","method":"CYP1A2 knockout mouse pharmacokinetic study; blood caffeine measurement; urine metabolite analysis; liver function tests; Western blot for other P450s","journal":"Pharmacogenetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockout mouse with full pharmacokinetic characterization and metabolite profiling, confirmation that other P450s unaffected","pmids":["8873215"],"is_preprint":false},{"year":1997,"finding":"CYP1A2 and CYP3A4 are both involved in demethylation of clozapine (CLZ) to desmethylclozapine (DCLZ); CYP3A4 is primarily responsible for N-oxidation of CLZ. CYP1A2 has lower Km and Vmax than CYP3A4 for demethylation, suggesting CYP1A2 is more important at low (therapeutic) CLZ concentrations. Demonstrated by chemical inhibitors (fluvoxamine, triacetyloleandomycin, ketoconazole), specific antibodies, and heterologous expression systems.","method":"Human liver microsomal incubations; chemical inhibitors; anti-CYP antibody inhibition; CYP expression systems; correlation analysis; enzyme kinetics (Km, Vmax)","journal":"British journal of clinical pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (inhibitors, antibodies, expressed enzymes, kinetics) in a single study","pmids":["9384460"],"is_preprint":false},{"year":1998,"finding":"CYP1A2 protein is absent in human fetal and neonatal livers and shows delayed ontogenesis, with levels increasing from 1–3 months postnatal and reaching 50% of adult values at one year. Methoxyresorufin demethylase activity (CYP1A2-selective) follows this ontogenic profile. In early neonates, CYP3A mediates the low residual imipramine demethylation before CYP1A2 onset.","method":"Immunoblot with polyclonal anti-rat CYP1A antibody; enzymatic activity assays (methoxyresorufin demethylase, imipramine demethylation); human liver bank analysis across developmental stages","journal":"European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — immunoblot plus enzyme activity, multiple developmental time points, clear ontogenic trajectory established","pmids":["9490065"],"is_preprint":false},{"year":1999,"finding":"CYP1A2 is not the sole enzyme responsible for 4-aminobiphenyl (4-ABP) N-hydroxylation in mice; in vivo hepatocarcinogenesis in Cyp1a2−/− mice showed no significant difference in overall tumor incidence compared to wild-type. In vitro studies confirmed another unidentified P450 contributes to 4-ABP N-hydroxylation in mice.","method":"Cyp1a2 knockout mouse neonatal bioassay; histological analysis of hepatic tumors and preneoplastic foci; in vitro microsomal N-hydroxylation assays with Cyp1a2−/− and wild-type microsomes","journal":"Carcinogenesis","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockout mouse in vivo carcinogenesis study plus supporting in vitro enzyme assays; negative result for CYP1A2 as rate-limiting step is rigorously established","pmids":["10469630"],"is_preprint":false},{"year":2000,"finding":"CYP1A2 is the major CYP isoform catalyzing lidocaine N-deethylation (MEGX formation) at low (therapeutically relevant) lidocaine concentrations (~60% inhibition by furafylline, >75% by anti-CYP1A1/2 antibodies), while CYP3A4 contribution increases at high lidocaine concentrations. CYP1A2 also almost exclusively catalyzes lidocaine 3-hydroxylation.","method":"Human liver microsomes; selective chemical inhibitors (furafylline, troleandomycin); immunoinhibition with anti-CYP antibodies; recombinant human CYP isoforms; enzyme kinetics","journal":"Drug metabolism and disposition: the biological fate of chemicals","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (chemical inhibition, immunoinhibition, recombinant enzymes) with concentration-dependent analysis","pmids":["10901707"],"is_preprint":false},{"year":2000,"finding":"Both CYP1A2 and CYP2D6 catalyze propranolol 4-hydroxylation in human liver microsomes, with CYP1A2 contributing ~45% and CYP2D6 ~55% of total activity. Enzyme kinetics showed CYP1A2 Km of ~21 µM and CYP2D6 Km of ~8.5 µM for (S)-4-hydroxypropranolol formation.","method":"Human liver microsomes; recombinant CYP enzyme screening (11 isoforms); correlation analysis with CYP1A2 marker activity; selective chemical inhibitors (furafylline, quinidine); enzyme kinetics","journal":"The Journal of pharmacology and experimental therapeutics","confidence":"High","confidence_rationale":"Tier 1 / Strong — comprehensive enzyme screening, correlation, inhibition and kinetic methods in a single study","pmids":["10945865"],"is_preprint":false},{"year":2000,"finding":"CYP1A2 is essential for hepatic uroporphyrin accumulation in hexachlorobenzene (HCBZ) and iron-induced murine uroporphyria: Cyp1a2−/− mice show no hepatic uroporphyrin accumulation even after additional HCBZ doses, while wild-type mice accumulate 300 nmol/g liver. HCBZ-induced uroporphyrinogen oxidation in microsomes was CYP1A2-dependent.","method":"Cyp1a2 knockout mouse; hepatic uroporphyrin measurement; Western immunoblotting for CYP proteins; microsomal uroporphyrinogen oxidation assay","journal":"Toxicology and applied pharmacology","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockout mouse with quantitative biochemical endpoints, Western blot confirmation, combined inducer and precursor treatments","pmids":["10631128"],"is_preprint":false},{"year":2003,"finding":"A heterozygous point mutation in the donor splice site of intron 6 (3534G>A) of CYP1A2 was identified as the likely cause of very low CYP1A2 activity (and high clozapine plasma concentrations) in a patient; this mutation is predicted to cause abnormal RNA splicing and a truncated nonfunctional enzyme. This is the first reported splice-site mutation in CYP1A2.","method":"Direct sequencing of all 7 exons, exon-intron boundaries, and 5'-flanking region; caffeine phenotyping; population screen of 100 Caucasians","journal":"British journal of clinical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — sequencing identifies mechanistic defect (splice site mutation) with phenotypic correlation; functional validation of truncated protein not directly shown","pmids":["12919186"],"is_preprint":false},{"year":2004,"finding":"CYP1A2 decreases microsomal reactive oxygen production (H2O2) possibly by acting as an 'electron sink,' reducing CYP2E1- and CYP1A1-mediated oxidative stress. Cyp1a2−/− mice showed significantly higher NADPH-dependent H2O2 production in microsomes compared to wild-type, and CYP1A2 inhibitor furafylline exacerbated H2O2 production proportional to degree of CYP1A2 inhibition.","method":"Cyp1a2 knockout mouse liver microsomes; NADPH-dependent H2O2 measurement; TCDD induction; furafylline inhibition; TBARS assay; membrane polarization anisotropy","journal":"Free radical biology & medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockout and chemical inhibitor approaches with multiple readouts (H2O2, TBARS, membrane polarization) in a single study","pmids":["14980704"],"is_preprint":false},{"year":2004,"finding":"CYP1A2 mediates pentoxifylline (PTX) metabolism in mice: Cyp1a2 knockout mice have significantly elevated serum PTX levels compared to wild-type at 20 minutes post-injection. Furafylline (selective CYP1A2 inhibitor) inhibits PTX metabolism in murine hepatic microsomes, and ciprofloxacin inhibits PTX metabolism without downregulating CYP1A2 protein.","method":"Cyp1a2 knockout mouse; furafylline inhibition; in vitro hepatic microsomal incubation; serum PTX measurement; Western blot for CYP1A2 and CYP2E1","journal":"Biochemical pharmacology","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockout mouse and selective inhibitor both confirm CYP1A2 role; drug interaction mechanism clarified","pmids":["15194011"],"is_preprint":false},{"year":2007,"finding":"Pyrene-induced CYP1A2 expression (protein, mRNA, and EROD/pyrene 1-hydroxylation activities) occurs in both AhR(+/+) and AhR(−/−) mice, demonstrating that pyrene-induced CYP1A2 is regulated by constitutive androstane receptor (CAR) rather than AhR. Pyrene simultaneously induced CAR and its target CYP2B10 in both genotypes.","method":"AhR knockout and wild-type mouse in vivo exposure; hepatic protein and mRNA expression by Western blot and RT-PCR; enzyme activity assays (EROD, MROD); CAR and CYP2B10 expression analysis","journal":"Toxicology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with orthogonal mRNA, protein, and activity measurements; clearly establishes CAR not AhR as regulator for pyrene induction","pmids":["17618724"],"is_preprint":false},{"year":2008,"finding":"Omeprazole induces both CYP1A1 and CYP1A2 transcription through a common regulatory region containing multiple AhR-binding motifs (nucleotides −464 to −1829 of human CYP1A1), identical to the region for beta-naphthoflavone and 3-methylcholanthrene induction, but omeprazole activates both CYP1A1 and CYP1A2 to similar extents while BNF and 3MC prefer CYP1A1.","method":"Transient transfection of dual reporter gene constructs with deletion constructs in human hepatoma cells; AhR-dependence confirmed","journal":"Biochemical pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reporter gene assays with multiple deletion constructs identifying specific regulatory region; single lab but orthogonal constructs","pmids":["18502397"],"is_preprint":false},{"year":2008,"finding":"Mouse Cyp1a1 and Cyp1a2 genes are arranged in head-to-head orientation separated by ~13.9 kb; eight consensus dioxin responsive elements (DREs) are present in this junction, with seven located within 1.4 kb upstream of Cyp1a1 but no conserved DREs in the proximal Cyp1a2 upstream region. This genomic architecture is conserved across human, mouse, cattle, dog, and rat.","method":"Comparative genomic DNA sequence analysis; identification of DRE motifs; evolutionary conservation analysis across mammalian genomes","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — comprehensive genomic sequence analysis across multiple species; mechanistic implication for differential AhR-mediated regulation; no functional reporter validation in this paper","pmids":["19026991"],"is_preprint":false},{"year":2009,"finding":"CYP1A2 gene expression in human liver is regulated by DNA methylation: extent of methylation of a CpG island near the translation start site inversely correlates with hepatic CYP1A2 mRNA levels. Methylation of two core CpG sites is strongly associated with CYP1A2 mRNA levels and allele-specific expression phenotype. CYP1A2 expression in hepatoma cells was induced by the demethylating agent 5-aza-2'-deoxycytidine.","method":"65 human liver samples; allele-specific expression analysis; CpG island methylation analysis; 5-aza-2'-deoxycytidine treatment of hepatoma cells; correlation analysis","journal":"The pharmacogenomics journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — methylation-expression correlation confirmed by pharmacological demethylation in cell line; multiple CpG sites analyzed in large human liver panel","pmids":["19274061"],"is_preprint":false},{"year":2015,"finding":"Functional characterization of 20 CYP1A2 amino acid substitution variants showed that CYP1A2*4, *6, *8, *15, *16, and *21 are completely inactive toward both phenacetin and 7-ethoxyresorufin. CYP1A2*11 shows markedly reduced activity with substrate-dependent changes in Km. CYP1A2*14 and *20 exhibit increased enzymatic activity compared to wild-type CYP1A2*1.","method":"Heterologous expression in COS-7 cells; enzyme kinetics (Km, Vmax) with two substrates (phenacetin O-deethylation, 7-ethoxyresorufin O-deethylation)","journal":"Drug metabolism and pharmacokinetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted expressed variant proteins with full enzyme kinetics using two substrates; comprehensive allele survey","pmids":["26022657"],"is_preprint":false},{"year":2019,"finding":"Using mice humanized for human CYP1A1/CYP1A2 combined with Cyp1a1/Cyp1a2 double knockout mice, CYP1A2 was shown to be constitutively expressed in the liver while both proteins are highly inducible by TCDD in liver, lung, kidney, and small intestine. Both CYP1A1 and CYP1A2 contribute to hepatic metabolism of 7-methoxy and 7-ethoxyresorufin; differential inhibition by quinidine allows quantitative partitioning of their respective contributions.","method":"Humanized CYP1A1/1A2 mice; Cyp1a1/Cyp1a2 knockout mice; microsomal enzyme kinetics; selective inhibition by quinidine; TCDD induction; tissue expression profiling","journal":"Drug metabolism and disposition: the biological fate of chemicals","confidence":"High","confidence_rationale":"Tier 2 / Strong — humanized and knockout mouse models combined with enzyme kinetic modeling; multiple tissues and substrates","pmids":["31147315"],"is_preprint":false},{"year":2021,"finding":"CYP1A2 acts as a tumor suppressor in hepatocellular carcinoma by directly binding to HIF-1α (confirmed by Co-immunoprecipitation), inducing ubiquitin-mediated degradation of HIF-1α, thereby inhibiting HIF-1α-mediated transcription of MET and reducing HGF/MET signaling pathway activation and MMP expression.","method":"Co-immunoprecipitation; Western blot; overexpression and knockdown in HCC cell lines; in vivo xenograft; Western blot; qRT-PCR; immunohistochemistry","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP establishes binding; multiple functional assays in vitro and in vivo; single lab with two orthogonal methods but ubiquitination mechanism not directly reconstituted","pmids":["33500715"],"is_preprint":false},{"year":2006,"finding":"Kupffer cell-derived proinflammatory cytokines (TNF-α and IL-1β) suppress hepatocyte CYP1A2 expression in sepsis via downregulation of AhR/ARNT; anti-TNF-α and anti-IL-1β antibodies attenuated CYP1A2 downregulation in co-culture. LPS alone did not suppress CYP1A2 without direct Kupffer cell–hepatocyte contact.","method":"Primary Kupffer cell and hepatocyte co-culture (with and without transwells); anti-cytokine antibodies; CLP rat sepsis model; curcumin pretreatment; CYP1A2, AhR, ARNT expression analysis","journal":"International journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro co-culture and in vivo sepsis model with antibody blockade; pathway (AhR/ARNT) identified mechanistically","pmids":["16820944"],"is_preprint":false},{"year":2019,"finding":"CYP1A2 contributes to alcohol-induced abnormal lipid metabolism through the PTEN/AKT/SREBP-1c pathway: siRNA-mediated knockdown or fluvoxamine inhibition of CYP1A2 in L02 cells reduced ethanol-induced ALT, triglycerides, and SREBP-1c expression, while modulation of PTEN/AKT upstream of SREBP-1c confirmed pathway involvement.","method":"siRNA knockdown; pharmacological inhibition with fluvoxamine; PTEN siRNA; bpv (PTEN inhibitor); Western blot for PTEN, p-AKT, SREBP-1c; ALT and triglyceride measurement in cell culture","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — loss-of-function with siRNA and chemical inhibitor plus pathway validation by PTEN manipulation; single lab, in vitro only","pmids":["30979496"],"is_preprint":false},{"year":2022,"finding":"CYP1A2 is induced by psoralen and isopsoralen via AhR-mediated transcriptional activation: both compounds bind AhR and activate its translocation from cytoplasm to nucleus, leading to transcriptional upregulation of CYP1A2, which mediates their hepatotoxicity. Shown in vitro and in vivo by AhR binding, nucleocytoplasmic shuttling, and CYP1A2 activity assays.","method":"HepG2 cells and mouse in vivo; cellular thermal shift assay; molecular docking; immunofluorescence (AhR translocation); CYP1A2 mRNA, protein, and phenacetin metabolism assays","journal":"Journal of ethnopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — thermal shift assay and nuclear translocation imaging establish AhR binding mechanism; CYP1A2 activity and mRNA confirmed in vivo and in vitro","pmids":["35872289"],"is_preprint":false},{"year":2022,"finding":"CYP1A2 is the major enzyme responsible for metabolic activation (N-hydroxylation/oxidation) of the fungicide carbendazim to a reactive electrophilic metabolite that forms glutathione conjugates and protein adducts, contributing to hepatotoxicity. Biliary and urinary conjugate metabolites were detected in rats, and protein adduction in primary hepatocytes correlated with cytotoxicity.","method":"Human and rat liver microsomal incubation; GSH and NAC trapping; LC-MS/MS metabolite identification; in vivo rat biliary/urinary metabolite detection; protein adduction in rat primary hepatocytes","journal":"Journal of agricultural and food chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with trapping and MS confirmation; in vivo rat metabolites; single lab","pmids":["35316061"],"is_preprint":false},{"year":2023,"finding":"Molecular dynamics and quantum chemical calculations on CYP1A2 crystal structure with docked melatonin predict that CYP1A2 catalyzes melatonin 6-hydroxylation (aromatic hydroxylation) and O-demethylation (forming N-acetylserotonin) via the heme-iron oxo intermediate; calculated barrier heights are consistent with experimental product distributions and explain species differences with CYP1A1.","method":"Molecular dynamics simulation (up to 1 µs); density functional theory (DFT) quantum chemical cluster models; starting from crystal structure coordinates; substrate docking","journal":"International journal of molecular sciences","confidence":"Low","confidence_rationale":"Tier 4 / Weak — computational-only study (MD + QM), no experimental validation of mechanism in this paper","pmids":["36835057"],"is_preprint":false}],"current_model":"CYP1A2 is a predominantly hepatic cytochrome P450 enzyme (constitutively expressed, absent in fetal/neonatal liver) that uses a heme-iron active site (with cysteine 456 as the thiolate ligand) to catalyze oxidative metabolism of diverse substrates including caffeine, theophylline, clozapine, lidocaine, propranolol, heterocyclic amines, and aflatoxin B1; its transcription is induced through AhR/ARNT-dependent binding to dioxin responsive elements (shared with CYP1A1 in a head-to-head genomic locus) by ligands including TCDD, 3-methylcholanthrene, and omeprazole, and is also regulated by DNA methylation of a proximal CpG island, suppressed in sepsis via Kupffer cell-derived cytokines (TNF-α/IL-1β) reducing AhR/ARNT, and induced by CAR (not AhR) in response to pyrene; beyond drug metabolism, CYP1A2 plays roles in reducing microsomal reactive oxygen production (acting as an electron sink to limit CYP2E1/CYP1A1-mediated H2O2), is essential for porphyrinogen oxidation leading to uroporphyria, suppresses hepatocellular carcinoma by binding HIF-1α and promoting its ubiquitin-mediated degradation to antagonize HGF/MET signaling, and participates in alcohol-induced lipid dysregulation through the PTEN/AKT/SREBP-1c pathway."},"narrative":{"mechanistic_narrative":"CYP1A2 is a constitutively expressed hepatic cytochrome P450 monooxygenase that uses a heme-iron active site, with cysteine 456 serving as the thiolate ligand, to catalyze oxidative metabolism of structurally diverse xenobiotics and drugs [PMID:6324134, PMID:8274012]. Its substrate spectrum established by reconstituted-enzyme and knockout-mouse studies includes aflatoxin B1 (4-hydroxylation to aflatoxin M1) [PMID:3137222], heterocyclic amines IQ and MeIQx (N-hydroxylation to mutagens) [PMID:8200083], caffeine, zoxazolamine, clozapine, lidocaine, propranolol, and pentoxifylline [PMID:8643688, PMID:8873215, PMID:9384460, PMID:10901707, PMID:10945865, PMID:15194011]; for several of these CYP1A2 dominates at low therapeutic concentrations while other P450s (CYP3A4, CYP2D6) contribute at higher concentrations [PMID:9384460, PMID:10901707, PMID:10945865]. CYP1A2 is the selective catalyst of methoxyresorufin O-demethylation, distinguishing it from CYP1A1 [PMID:8274012, PMID:31147315]. Beyond metabolism, CYP1A2 limits microsomal reactive oxygen production by acting as an electron sink that suppresses CYP2E1/CYP1A1-mediated H2O2 generation [PMID:14980704], is required for hepatic uroporphyrin accumulation through uroporphyrinogen oxidation in murine uroporphyria [PMID:10631128], and acts as a tumor suppressor in hepatocellular carcinoma by binding HIF-1α and promoting its ubiquitin-mediated degradation to antagonize HGF/MET signaling [PMID:33500715]. CYP1A2 transcription is induced through AhR-dependent binding to dioxin responsive elements shared with CYP1A1 at a conserved head-to-head genomic locus, by ligands including 3-methylcholanthrene, beta-naphthoflavone, omeprazole, and psoralen/isopsoralen [PMID:18502397, PMID:19026991, PMID:35872289], but pyrene-induced expression is mediated by the constitutive androstane receptor rather than AhR [PMID:17618724]. Expression is further controlled by DNA methylation of a proximal CpG island [PMID:19274061] and is suppressed in sepsis via Kupffer cell-derived TNF-α/IL-1β acting through downregulation of AhR/ARNT [PMID:16820944]. The enzyme is absent in fetal and neonatal liver with delayed postnatal ontogenesis [PMID:9490065], and human expression is highly variable, partly through splice-site mutations and amino acid variants that abolish or alter activity [PMID:8287062, PMID:12919186, PMID:26022657].","teleology":[{"year":1984,"claim":"Established the primary structure and the heme-iron coordination chemistry of the CYP1A2 ortholog, identifying cysteine 456 as the active-site thiolate ligand and mapping the gene physically next to CYP1A1.","evidence":"cDNA cloning/sequencing and cysteinyl peptide analysis plus somatic cell hybrid chromosome mapping in mouse","pmids":["6324134","6328503"],"confidence":"High","gaps":["Cysteine 456 thiolate assignment was sequence-based, not validated by mutagenesis","No catalytic activity demonstrated at this stage"]},{"year":1988,"claim":"Resolved which enzyme detoxifies aflatoxin B1 by showing CYP1A2 itself catalyzes AFB1 4-hydroxylation, establishing direct enzyme-substrate function.","evidence":"Recombinant vaccinia virus expression of CYP1A2 cDNA with in vitro AFB1 metabolic assay","pmids":["3137222"],"confidence":"High","gaps":["Did not address relative contribution versus other P450s in vivo","No structural basis for substrate selectivity"]},{"year":1993,"claim":"Defined the catalytic fingerprint that distinguishes CYP1A2 from CYP1A1 and provided isoform-selective chemical tools (furafylline), enabling all later attribution of activities to CYP1A2.","evidence":"Vaccinia cDNA expression with enzyme kinetics and selective inhibition (MROD vs EROD/BaP hydroxylase)","pmids":["8274012"],"confidence":"High","gaps":["Inhibitor selectivity is partial (alpha-naphthoflavone inhibits both isoforms)","Mouse enzyme; human equivalence assumed"]},{"year":1994,"claim":"Linked CYP1A2's constitutive hepatic expression to procarcinogen activation, showing it is the primary enzyme bioactivating heterocyclic amines IQ and MeIQx to mutagens.","evidence":"Human/primate liver microsomes, Ames mutagenicity assay, CYP-level correlation, and TCDD induction in marmoset","pmids":["8200083"],"confidence":"High","gaps":["PhIP activation shared with CYP1A1, not CYP1A2-specific","Correlative attribution rather than purified enzyme for all activities"]},{"year":1996,"claim":"Established in vivo physiological substrate dependence using genetic knockouts, proving CYP1A2 is rate-determining for zoxazolamine and caffeine clearance while other P450s partially compensate.","evidence":"Cyp1a2−/− knockout mice with paralysis test and pharmacokinetic/metabolite profiling","pmids":["8643688","8873215"],"confidence":"High","gaps":["Identity of compensating caffeine-metabolizing P450s not determined","Mouse pharmacokinetics may differ from human"]},{"year":1997,"claim":"Clarified clinically relevant drug metabolism by showing CYP1A2 dominates clozapine demethylation at therapeutic concentrations through its low Km, with CYP3A4 dominating at higher concentrations.","evidence":"Human liver microsomes with chemical inhibitors, anti-CYP antibodies, expression systems, and kinetics","pmids":["9384460"],"confidence":"High","gaps":["Relative in vivo contribution depends on hepatic enzyme abundance not measured here"]},{"year":1998,"claim":"Defined the developmental trajectory of CYP1A2, establishing its absence in fetal/neonatal liver and delayed postnatal onset, explaining pediatric drug-handling differences.","evidence":"Immunoblot and MROD/imipramine activity assays across a developmental human liver bank","pmids":["9490065"],"confidence":"High","gaps":["Molecular trigger of postnatal induction not identified","Antibody is anti-rat CYP1A, cross-reactivity caveats"]},{"year":2000,"claim":"Extended the CYP1A2 substrate map to lidocaine and propranolol, quantifying its concentration-dependent and fractional contributions relative to CYP3A4 and CYP2D6.","evidence":"Human liver microsomes, recombinant isoform screening, selective inhibition, and kinetics","pmids":["10901707","10945865"],"confidence":"High","gaps":["In vivo metabolic partitioning in humans not directly measured"]},{"year":2000,"claim":"Revealed a non-xenobiotic physiological role: CYP1A2 is required for hepatic uroporphyrinogen oxidation and uroporphyria, linking the enzyme to porphyrin metabolism.","evidence":"Cyp1a2−/− mice with HCBZ/iron treatment, uroporphyrin quantification, and microsomal oxidation assay","pmids":["10631128"],"confidence":"High","gaps":["Catalytic mechanism of uroporphyrinogen oxidation not reconstituted","Human relevance not directly shown"]},{"year":1999,"claim":"Tested but did not confirm CYP1A2 as a rate-limiting carcinogen activator in vivo, showing it is not the sole enzyme for 4-aminobiphenyl N-hydroxylation in mice.","evidence":"Cyp1a2−/− neonatal hepatocarcinogenesis bioassay plus in vitro microsomal N-hydroxylation","pmids":["10469630"],"confidence":"High","gaps":["Identity of the alternative N-hydroxylating P450 unknown","Negative result; may not extrapolate to humans"]},{"year":2004,"claim":"Identified a protective antioxidant function whereby CYP1A2 acts as an electron sink limiting CYP2E1/CYP1A1-mediated microsomal H2O2 production.","evidence":"Cyp1a2−/− microsomes, NADPH-dependent H2O2 and TBARS assays, furafylline inhibition","pmids":["14980704"],"confidence":"High","gaps":["Molecular mechanism of electron-sink behavior not biochemically resolved","In vivo physiological significance not quantified"]},{"year":2006,"claim":"Defined an inflammatory suppression mechanism, showing Kupffer cell TNF-α/IL-1β downregulate hepatocyte CYP1A2 via AhR/ARNT during sepsis, requiring direct cell contact.","evidence":"Kupffer cell–hepatocyte co-culture with transwells and anti-cytokine antibodies plus CLP rat sepsis model","pmids":["16820944"],"confidence":"Medium","gaps":["Contact-dependent signal beyond cytokines not identified","AhR/ARNT downregulation mechanism not resolved at transcriptional level"]},{"year":2007,"claim":"Distinguished receptor-specific induction routes, demonstrating pyrene induces CYP1A2 through CAR rather than AhR.","evidence":"AhR knockout vs wild-type mice with mRNA, protein, and EROD/MROD activity plus CAR/CYP2B10 readouts","pmids":["17618724"],"confidence":"High","gaps":["Direct CAR binding to CYP1A2 regulatory elements not shown","Generality across other CAR ligands untested"]},{"year":2008,"claim":"Mapped the cis-regulatory architecture of AhR-mediated induction, identifying a shared CYP1A1/CYP1A2 regulatory region with dioxin responsive elements and a conserved head-to-head genomic locus.","evidence":"Dual reporter deletion constructs in hepatoma cells (omeprazole/BNF/3MC) and comparative genomic DRE analysis across mammals","pmids":["18502397","19026991"],"confidence":"High","gaps":["Lack of proximal CYP1A2 DREs leaves the precise enhancer driving CYP1A2 unresolved","Genomic DRE analysis lacks functional reporter validation"]},{"year":2009,"claim":"Established epigenetic control of CYP1A2, showing CpG island methylation inversely controls hepatic expression and underlies allele-specific expression variability.","evidence":"Methylation-expression correlation in 65 human livers and 5-aza-2'-deoxycytidine induction in hepatoma cells","pmids":["19274061"],"confidence":"High","gaps":["Transcription factors recruited to the methylated region not identified","Causal direction at single CpG sites inferred from correlation plus pharmacology"]},{"year":2003,"claim":"Provided a genetic mechanism for interindividual deficiency, identifying splice-site and abnormal-splicing variants causing low CYP1A2 activity and altered drug response.","evidence":"Direct sequencing with caffeine phenotyping and population screening; earlier exon-4 deletion variant","pmids":["12919186","8287062"],"confidence":"Medium","gaps":["Functional translation/protein products of truncated transcripts not validated","Single-patient observations require population confirmation"]},{"year":2015,"claim":"Systematically defined the functional consequences of coding variants, identifying null, reduced-function, and gain-of-function CYP1A2 alleles.","evidence":"Heterologous expression of 20 variants in COS-7 cells with kinetics on two substrates","pmids":["26022657"],"confidence":"High","gaps":["In vivo pharmacokinetic consequences of variants not measured","Substrate-dependence implies activity calls may vary for other substrates"]},{"year":2019,"claim":"Quantitatively partitioned hepatic CYP1A1 vs CYP1A2 contributions and confirmed constitutive hepatic CYP1A2 with broad inducibility using humanized and double-knockout mice.","evidence":"Humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 knockout mice with microsomal kinetics, quinidine inhibition, and TCDD tissue profiling","pmids":["31147315"],"confidence":"High","gaps":["Humanized model may not fully recapitulate human regulatory context"]},{"year":2019,"claim":"Connected CYP1A2 to lipid pathophysiology, implicating it in alcohol-induced lipid dysregulation through the PTEN/AKT/SREBP-1c pathway.","evidence":"siRNA knockdown and fluvoxamine inhibition in L02 cells with PTEN manipulation and Western blots","pmids":["30979496"],"confidence":"Medium","gaps":["In vitro single cell line only; no in vivo confirmation","Direct enzymatic link between CYP1A2 catalysis and PTEN/AKT not established"]},{"year":2021,"claim":"Defined a non-catalytic tumor-suppressor function: CYP1A2 binds HIF-1α and drives its ubiquitin-mediated degradation to suppress HGF/MET signaling in hepatocellular carcinoma.","evidence":"Co-immunoprecipitation, overexpression/knockdown in HCC cell lines, and in vivo xenografts","pmids":["33500715"],"confidence":"Medium","gaps":["Ubiquitination mechanism not reconstituted; E3 ligase not identified","Co-IP without reciprocal structural validation of the CYP1A2–HIF-1α interface"]},{"year":2022,"claim":"Extended induction and bioactivation roles to herbal/agricultural toxicants, showing AhR-mediated induction by psoralen/isopsoralen and CYP1A2-dependent bioactivation of carbendazim to reactive adduct-forming metabolites.","evidence":"Thermal shift, docking, AhR translocation imaging, microsomal trapping/LC-MS, and in vivo rat metabolite detection","pmids":["35872289","35316061"],"confidence":"Medium","gaps":["Direct AhR-DRE engagement for psoralen not demonstrated by ChIP","Single-lab bioactivation studies for carbendazim"]},{"year":2023,"claim":"Provided a computational mechanistic model of CYP1A2 catalysis on melatonin, predicting 6-hydroxylation and O-demethylation via the heme-iron oxo intermediate.","evidence":"Molecular dynamics and DFT quantum chemical calculations on the CYP1A2 crystal structure with docked melatonin","pmids":["36835057"],"confidence":"Low","gaps":["Computational-only; no experimental validation in this study","Predicted product distribution not biochemically confirmed here"]},{"year":null,"claim":"How CYP1A2's catalytic monooxygenase function mechanistically integrates with its non-catalytic regulatory roles (HIF-1α degradation, electron-sink antioxidant activity, lipid signaling) remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural definition of the CYP1A2–HIF-1α interaction","E3 ligase mediating HIF-1α degradation unidentified","Biochemical basis of electron-sink behavior not resolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[2,4,5,11,12,15]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[23]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[15,22]}],"pathway":[{"term_id":"R-HSA-9748784","term_label":"Drug ADME","supporting_discovery_ids":[7,8,11,12]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[2,13,25]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[23,27]}],"complexes":[],"partners":["AHR","ARNT","HIF1A"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P05177","full_name":"Cytochrome P450 1A2","aliases":["CYPIA2","Cholesterol 25-hydroxylase","Cytochrome P(3)450","Cytochrome P450 4","Cytochrome P450-P3","Hydroperoxy icosatetraenoate dehydratase"],"length_aa":516,"mass_kda":58.4,"function":"A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins (PubMed:10681376, PubMed:11555828, PubMed:12865317, PubMed:19965576, PubMed:9435160). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:10681376, PubMed:11555828, PubMed:12865317, PubMed:19965576, PubMed:9435160). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:11555828, PubMed:12865317). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2 (PubMed:11555828, PubMed:12865317). Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). May act as a major enzyme for all-trans retinoic acid biosynthesis in the liver. Catalyzes two successive oxidative transformation of all-trans retinol to all-trans retinal and then to the active form all-trans retinoic acid (PubMed:10681376). Primarily catalyzes stereoselective epoxidation of the last double bond of polyunsaturated fatty acids (PUFA), displaying a strong preference for the (R,S) stereoisomer (PubMed:19965576). Catalyzes bisallylic hydroxylation and omega-1 hydroxylation of PUFA (PubMed:9435160). May also participate in eicosanoids metabolism by converting hydroperoxide species into oxo metabolites (lipoxygenase-like reaction, NADPH-independent) (PubMed:21068195). Plays a role in the oxidative metabolism of xenobiotics. Catalyzes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin (PubMed:14725854). Metabolizes caffeine via N3-demethylation (Probable)","subcellular_location":"Endoplasmic reticulum membrane; Microsome membrane","url":"https://www.uniprot.org/uniprotkb/P05177/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CYP1A2","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CYP1A2","total_profiled":1310},"omim":[{"mim_id":"601771","title":"CYTOCHROME P450, SUBFAMILY I, POLYPEPTIDE 1; CYP1B1","url":"https://www.omim.org/entry/601771"},{"mim_id":"601130","title":"CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9","url":"https://www.omim.org/entry/601130"},{"mim_id":"300435","title":"PROGESTERONE RECEPTOR MEMBRANE COMPONENT 1; PGRMC1","url":"https://www.omim.org/entry/300435"},{"mim_id":"176100","title":"PORPHYRIA CUTANEA TARDA","url":"https://www.omim.org/entry/176100"},{"mim_id":"168600","title":"PARKINSON DISEASE, LATE-ONSET; PD","url":"https://www.omim.org/entry/168600"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"liver","ntpm":478.4}],"url":"https://www.proteinatlas.org/search/CYP1A2"},"hgnc":{"alias_symbol":["P3-450","CP12"],"prev_symbol":[]},"alphafold":{"accession":"P05177","domains":[{"cath_id":"1.10.630.10","chopping":"38-61_68-512","consensus_level":"medium","plddt":97.2155,"start":38,"end":512}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P05177","model_url":"https://alphafold.ebi.ac.uk/files/AF-P05177-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P05177-F1-predicted_aligned_error_v6.png","plddt_mean":95.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CYP1A2","jax_strain_url":"https://www.jax.org/strain/search?query=CYP1A2"},"sequence":{"accession":"P05177","fasta_url":"https://rest.uniprot.org/uniprotkb/P05177.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P05177/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P05177"}},"corpus_meta":[{"pmid":"16522833","id":"PMC_16522833","title":"Coffee, CYP1A2 genotype, and risk of myocardial infarction.","date":"2006","source":"JAMA","url":"https://pubmed.ncbi.nlm.nih.gov/16522833","citation_count":320,"is_preprint":false},{"pmid":"1458773","id":"PMC_1458773","title":"Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities.","date":"1992","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/1458773","citation_count":269,"is_preprint":false},{"pmid":"16128905","id":"PMC_16128905","title":"Assessment of CYP1A2 activity in clinical practice: why, how, and when?","date":"2005","source":"Basic & clinical pharmacology & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/16128905","citation_count":222,"is_preprint":false},{"pmid":"18466106","id":"PMC_18466106","title":"Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms.","date":"2008","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/18466106","citation_count":205,"is_preprint":false},{"pmid":"17370067","id":"PMC_17370067","title":"Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.","date":"2007","source":"European journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17370067","citation_count":202,"is_preprint":false},{"pmid":"9384460","id":"PMC_9384460","title":"The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine.","date":"1997","source":"British journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/9384460","citation_count":193,"is_preprint":false},{"pmid":"9490065","id":"PMC_9490065","title":"Delayed ontogenesis of CYP1A2 in the human liver.","date":"1998","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9490065","citation_count":157,"is_preprint":false},{"pmid":"8287062","id":"PMC_8287062","title":"Expression of CYP1A1 and CYP1A2 genes in human liver.","date":"1993","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/8287062","citation_count":145,"is_preprint":false},{"pmid":"9689144","id":"PMC_9689144","title":"Evolutionary conserved light regulation of Calvin cycle activity by NADPH-mediated reversible phosphoribulokinase/CP12/ glyceraldehyde-3-phosphate dehydrogenase complex dissociation.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9689144","citation_count":145,"is_preprint":false},{"pmid":"29509641","id":"PMC_29509641","title":"Caffeine, CYP1A2 Genotype, and Endurance Performance in Athletes.","date":"2018","source":"Medicine and science in sports and exercise","url":"https://pubmed.ncbi.nlm.nih.gov/29509641","citation_count":140,"is_preprint":false},{"pmid":"8200083","id":"PMC_8200083","title":"Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human.","date":"1994","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/8200083","citation_count":135,"is_preprint":false},{"pmid":"9294236","id":"PMC_9294236","title":"CP12 provides a new mode of light regulation of Calvin cycle activity in higher plants.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9294236","citation_count":126,"is_preprint":false},{"pmid":"8643688","id":"PMC_8643688","title":"Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8643688","citation_count":122,"is_preprint":false},{"pmid":"21357676","id":"PMC_21357676","title":"Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption.","date":"2011","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21357676","citation_count":107,"is_preprint":false},{"pmid":"12846565","id":"PMC_12846565","title":"The small protein CP12: a protein linker for supramolecular complex assembly.","date":"2003","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12846565","citation_count":99,"is_preprint":false},{"pmid":"15206669","id":"PMC_15206669","title":"Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene.","date":"2004","source":"Journal of clinical psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15206669","citation_count":95,"is_preprint":false},{"pmid":"15047759","id":"PMC_15047759","title":"Emergence of new regulatory mechanisms in the Benson-Calvin pathway via protein-protein interactions: a glyceraldehyde-3-phosphate dehydrogenase/CP12/phosphoribulokinase complex.","date":"2004","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/15047759","citation_count":92,"is_preprint":false},{"pmid":"21281405","id":"PMC_21281405","title":"Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease.","date":"2011","source":"European journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21281405","citation_count":87,"is_preprint":false},{"pmid":"9110357","id":"PMC_9110357","title":"Lifestyle and nutritional correlates of cytochrome CYP1A2 activity: inverse associations with plasma lutein and alpha-tocopherol.","date":"1997","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/9110357","citation_count":83,"is_preprint":false},{"pmid":"10901707","id":"PMC_10901707","title":"Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans.","date":"2000","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/10901707","citation_count":80,"is_preprint":false},{"pmid":"24523724","id":"PMC_24523724","title":"The CP12 protein family: a thioredoxin-mediated metabolic switch?","date":"2014","source":"Frontiers in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/24523724","citation_count":74,"is_preprint":false},{"pmid":"16609368","id":"PMC_16609368","title":"Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype.","date":"2006","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/16609368","citation_count":74,"is_preprint":false},{"pmid":"15466009","id":"PMC_15466009","title":"Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction.","date":"2004","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15466009","citation_count":67,"is_preprint":false},{"pmid":"22988853","id":"PMC_22988853","title":"An intrinsically disordered protein, CP12: jack of all trades and master of the Calvin cycle.","date":"2012","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/22988853","citation_count":60,"is_preprint":false},{"pmid":"22854411","id":"PMC_22854411","title":"Associations between polymorphisms in the AHR and CYP1A1-CYP1A2 gene regions and habitual caffeine consumption.","date":"2012","source":"The American journal of clinical nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/22854411","citation_count":60,"is_preprint":false},{"pmid":"8873215","id":"PMC_8873215","title":"Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2.","date":"1996","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/8873215","citation_count":60,"is_preprint":false},{"pmid":"22554278","id":"PMC_22554278","title":"Measurement of CYP1A2 activity: a focus on caffeine as a probe.","date":"2012","source":"Current drug metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22554278","citation_count":59,"is_preprint":false},{"pmid":"18502397","id":"PMC_18502397","title":"Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements.","date":"2008","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18502397","citation_count":59,"is_preprint":false},{"pmid":"6324134","id":"PMC_6324134","title":"Mouse cytochrome P3-450: complete cDNA and amino acid sequence.","date":"1984","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/6324134","citation_count":57,"is_preprint":false},{"pmid":"12732846","id":"PMC_12732846","title":"Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma.","date":"2003","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/12732846","citation_count":55,"is_preprint":false},{"pmid":"10469630","id":"PMC_10469630","title":"CYP1A2 is not the primary enzyme responsible for 4-aminobiphenyl-induced hepatocarcinogenesis in mice.","date":"1999","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/10469630","citation_count":55,"is_preprint":false},{"pmid":"3137222","id":"PMC_3137222","title":"Cytochrome P3-450 cDNA encodes aflatoxin B1-4-hydroxylase.","date":"1988","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3137222","citation_count":53,"is_preprint":false},{"pmid":"10634135","id":"PMC_10634135","title":"Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine.","date":"1999","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/10634135","citation_count":52,"is_preprint":false},{"pmid":"18159984","id":"PMC_18159984","title":"Association of CYP1A1, CYP1A2, GSTM1 and NAT2 gene polymorphisms with colorectal cancer and smoking.","date":"2007","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/18159984","citation_count":52,"is_preprint":false},{"pmid":"22492992","id":"PMC_22492992","title":"Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hypertension.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22492992","citation_count":51,"is_preprint":false},{"pmid":"10945865","id":"PMC_10945865","title":"CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences.","date":"2000","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/10945865","citation_count":50,"is_preprint":false},{"pmid":"12919186","id":"PMC_12919186","title":"Identification of a novel splice-site mutation in the CYP1A2 gene.","date":"2003","source":"British journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12919186","citation_count":49,"is_preprint":false},{"pmid":"8274012","id":"PMC_8274012","title":"Enzyme-kinetic and immunochemical characteristics of mouse cDNA-expressed, microsomal, and purified CYP1A1 and CYP1A2.","date":"1993","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/8274012","citation_count":48,"is_preprint":false},{"pmid":"11849738","id":"PMC_11849738","title":"Induction of CYP1A1 and CYP1A2 expressions by prototypic and atypical inducers in the human lung.","date":"2002","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/11849738","citation_count":47,"is_preprint":false},{"pmid":"19274061","id":"PMC_19274061","title":"Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers.","date":"2009","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/19274061","citation_count":47,"is_preprint":false},{"pmid":"14980704","id":"PMC_14980704","title":"Cyp1a2 protects against reactive oxygen production in mouse liver microsomes.","date":"2004","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/14980704","citation_count":47,"is_preprint":false},{"pmid":"23184231","id":"PMC_23184231","title":"Comparative analysis of 126 cyanobacterial genomes reveals evidence of functional diversity among homologs of the redox-regulated CP12 protein.","date":"2012","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/23184231","citation_count":47,"is_preprint":false},{"pmid":"10631128","id":"PMC_10631128","title":"CYP1A2 is essential in murine uroporphyria caused by hexachlorobenzene and iron.","date":"2000","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10631128","citation_count":47,"is_preprint":false},{"pmid":"24211189","id":"PMC_24211189","title":"CP12-mediated protection of Calvin-Benson cycle enzymes from oxidative stress.","date":"2013","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/24211189","citation_count":46,"is_preprint":false},{"pmid":"6328503","id":"PMC_6328503","title":"Localization of cytochrome P1-450 and P3-450 genes to mouse chromosome 9.","date":"1984","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/6328503","citation_count":46,"is_preprint":false},{"pmid":"32823594","id":"PMC_32823594","title":"Effects of CYP1A2 and ADORA2A Genotypes on the Ergogenic Response to Caffeine in Professional Handball Players.","date":"2020","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/32823594","citation_count":43,"is_preprint":false},{"pmid":"33403509","id":"PMC_33403509","title":"Novel insights on caffeine supplementation, CYP1A2 genotype, physiological responses and exercise performance.","date":"2021","source":"European journal of applied physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33403509","citation_count":42,"is_preprint":false},{"pmid":"20080081","id":"PMC_20080081","title":"CYP1A1, CYP1A2 and CYBA gene polymorphisms associated with oxidative stress in COPD.","date":"2010","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20080081","citation_count":42,"is_preprint":false},{"pmid":"29071751","id":"PMC_29071751","title":"PXR mediated induction of CYP3A4, CYP1A2, and P-gp by Mitragyna speciosa and its alkaloids.","date":"2017","source":"Phytotherapy research : PTR","url":"https://pubmed.ncbi.nlm.nih.gov/29071751","citation_count":42,"is_preprint":false},{"pmid":"31147315","id":"PMC_31147315","title":"Defining the Contribution of CYP1A1 and CYP1A2 to Drug Metabolism Using Humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 Knockout Mice.","date":"2019","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/31147315","citation_count":42,"is_preprint":false},{"pmid":"17477782","id":"PMC_17477782","title":"NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status.","date":"2007","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/17477782","citation_count":42,"is_preprint":false},{"pmid":"30789308","id":"PMC_30789308","title":"Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics.","date":"2019","source":"Journal of psychopharmacology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/30789308","citation_count":41,"is_preprint":false},{"pmid":"20559687","id":"PMC_20559687","title":"CYP1A2 polymorphisms, occupational and environmental exposures and risk of bladder cancer.","date":"2010","source":"European journal of epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/20559687","citation_count":41,"is_preprint":false},{"pmid":"16490169","id":"PMC_16490169","title":"Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.","date":"2006","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/16490169","citation_count":40,"is_preprint":false},{"pmid":"17366540","id":"PMC_17366540","title":"Ontogeny of hepatic CYP1A2 and CYP2E1 expression in rat.","date":"2007","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/17366540","citation_count":39,"is_preprint":false},{"pmid":"18266760","id":"PMC_18266760","title":"Exploring CP12 binding proteins revealed aldolase as a new partner for the phosphoribulokinase/glyceraldehyde 3-phosphate dehydrogenase/CP12 complex--purification and kinetic characterization of this enzyme from Chlamydomonas reinhardtii.","date":"2008","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/18266760","citation_count":39,"is_preprint":false},{"pmid":"16427344","id":"PMC_16427344","title":"Construction of a 3D model of CP12, a protein linker.","date":"2006","source":"Journal of molecular graphics & modelling","url":"https://pubmed.ncbi.nlm.nih.gov/16427344","citation_count":38,"is_preprint":false},{"pmid":"28135712","id":"PMC_28135712","title":"Gene-Environment Interaction in Parkinson's Disease: Coffee, ADORA2A, and CYP1A2.","date":"2016","source":"Neuroepidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/28135712","citation_count":37,"is_preprint":false},{"pmid":"19287002","id":"PMC_19287002","title":"CP12 from Chlamydomonas reinhardtii, a permanent specific \"chaperone-like\" protein of glyceraldehyde-3-phosphate dehydrogenase.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19287002","citation_count":37,"is_preprint":false},{"pmid":"22648710","id":"PMC_22648710","title":"CYP1A2 and coffee intake and the modifying effect of sex, age, and smoking.","date":"2012","source":"The American journal of clinical nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/22648710","citation_count":37,"is_preprint":false},{"pmid":"14743400","id":"PMC_14743400","title":"Constitutive and inducible expression of cytochromes P4501A (CYP1A1 and CYP1A2) in normal prostate and prostate cancer cells.","date":"2004","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14743400","citation_count":35,"is_preprint":false},{"pmid":"33500715","id":"PMC_33500715","title":"CYP1A2 suppresses hepatocellular carcinoma through antagonizing HGF/MET signaling.","date":"2021","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/33500715","citation_count":34,"is_preprint":false},{"pmid":"19202560","id":"PMC_19202560","title":"Sulforaphane and its analogues inhibit CYP1A1 and CYP1A2 activity induced by benzo[a]pyrene.","date":"2009","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/19202560","citation_count":34,"is_preprint":false},{"pmid":"19332078","id":"PMC_19332078","title":"CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population.","date":"2009","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/19332078","citation_count":34,"is_preprint":false},{"pmid":"30458266","id":"PMC_30458266","title":"The azole fungicide tebuconazole affects human CYP1A1 and CYP1A2 expression by an aryl hydrocarbon receptor-dependent pathway.","date":"2018","source":"Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association","url":"https://pubmed.ncbi.nlm.nih.gov/30458266","citation_count":33,"is_preprint":false},{"pmid":"10096258","id":"PMC_10096258","title":"Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2.","date":"1999","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/10096258","citation_count":31,"is_preprint":false},{"pmid":"16803460","id":"PMC_16803460","title":"Mapping of the interaction site of CP12 with glyceraldehyde-3-phosphate dehydrogenase from Chlamydomonas reinhardtii. Functional consequences for glyceraldehyde-3-phosphate dehydrogenase.","date":"2006","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/16803460","citation_count":30,"is_preprint":false},{"pmid":"16820944","id":"PMC_16820944","title":"Suppression of hepatocyte CYP1A2 expression by Kupffer cells via AhR pathway: the central role of proinflammatory cytokines.","date":"2006","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16820944","citation_count":29,"is_preprint":false},{"pmid":"19099541","id":"PMC_19099541","title":"Mapping of a copper-binding site on the small CP12 chloroplastic protein of Chlamydomonas reinhardtii using top-down mass spectrometry and site-directed mutagenesis.","date":"2009","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/19099541","citation_count":28,"is_preprint":false},{"pmid":"17618724","id":"PMC_17618724","title":"Pyrene-induced CYP1A2 and SULT1A1 may be regulated by CAR and not by AhR.","date":"2007","source":"Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/17618724","citation_count":27,"is_preprint":false},{"pmid":"25090458","id":"PMC_25090458","title":"CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.","date":"2015","source":"Therapeutic drug monitoring","url":"https://pubmed.ncbi.nlm.nih.gov/25090458","citation_count":27,"is_preprint":false},{"pmid":"1482679","id":"PMC_1482679","title":"Expression and regulation of cytochrome P-450I genes (CYP1A1 and CYP1A2) in the rat alimentary tract.","date":"1992","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/1482679","citation_count":27,"is_preprint":false},{"pmid":"14574441","id":"PMC_14574441","title":"Constitutive and inducible levels of CYP1A1 and CYP1A2 in rat cerebral cortex and cerebellum.","date":"2003","source":"Archives of toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/14574441","citation_count":27,"is_preprint":false},{"pmid":"12790158","id":"PMC_12790158","title":"Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene.","date":"2003","source":"Journal of psychiatry & neuroscience : JPN","url":"https://pubmed.ncbi.nlm.nih.gov/12790158","citation_count":27,"is_preprint":false},{"pmid":"36330266","id":"PMC_36330266","title":"CP12 fine-tunes the Calvin-Benson cycle and carbohydrate metabolism in cyanobacteria.","date":"2022","source":"Frontiers in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/36330266","citation_count":25,"is_preprint":false},{"pmid":"22955105","id":"PMC_22955105","title":"CP12 residues involved in the formation and regulation of the glyceraldehyde-3-phosphate dehydrogenase-CP12-phosphoribulokinase complex in Chlamydomonas reinhardtii.","date":"2012","source":"Molecular bioSystems","url":"https://pubmed.ncbi.nlm.nih.gov/22955105","citation_count":25,"is_preprint":false},{"pmid":"19026991","id":"PMC_19026991","title":"Conserved genomic structure of the Cyp1a1 and Cyp1a2 loci and their dioxin responsive elements cluster.","date":"2008","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19026991","citation_count":24,"is_preprint":false},{"pmid":"33260381","id":"PMC_33260381","title":"Screening of Human CYP1A2 and CYP3A4 Inhibitors from Seaweed In Silico and In Vitro.","date":"2020","source":"Marine drugs","url":"https://pubmed.ncbi.nlm.nih.gov/33260381","citation_count":22,"is_preprint":false},{"pmid":"15194011","id":"PMC_15194011","title":"Role of CYP1A2 and CYP2E1 in the pentoxifylline ciprofloxacin drug interaction.","date":"2004","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15194011","citation_count":21,"is_preprint":false},{"pmid":"7493548","id":"PMC_7493548","title":"3-Methylcholanthrene and pyridine effects on CYP1A1 and CYP1A2 expression in rat renal tissue.","date":"1995","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/7493548","citation_count":21,"is_preprint":false},{"pmid":"23167834","id":"PMC_23167834","title":"Association between common CYP1A2 polymorphisms and theophylline metabolism in non-smoking healthy volunteers.","date":"2012","source":"Basic & clinical pharmacology & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/23167834","citation_count":21,"is_preprint":false},{"pmid":"29915055","id":"PMC_29915055","title":"Structural and functional insights into the unique CBS-CP12 fusion protein family in cyanobacteria.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29915055","citation_count":20,"is_preprint":false},{"pmid":"27021090","id":"PMC_27021090","title":"CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects.","date":"2016","source":"Bulletin of experimental biology and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27021090","citation_count":20,"is_preprint":false},{"pmid":"33024249","id":"PMC_33024249","title":"Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population.","date":"2020","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/33024249","citation_count":20,"is_preprint":false},{"pmid":"7750163","id":"PMC_7750163","title":"Regulation of cytochrome P-450 isozymes CYP1A1, CYP1A2 and CYP2B10 by three benzodioxole compounds.","date":"1995","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/7750163","citation_count":20,"is_preprint":false},{"pmid":"18703023","id":"PMC_18703023","title":"Comparison of CYP1A2 and NAT2 phenotypes between black and white smokers.","date":"2008","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18703023","citation_count":20,"is_preprint":false},{"pmid":"9364010","id":"PMC_9364010","title":"Marmoset CYP1A2: primary structure and constitutive expression in livers.","date":"1997","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/9364010","citation_count":20,"is_preprint":false},{"pmid":"11012552","id":"PMC_11012552","title":"Parkinson's disease and CYP1A2 activity.","date":"2000","source":"British journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11012552","citation_count":19,"is_preprint":false},{"pmid":"29501381","id":"PMC_29501381","title":"Cryptic Disorder Out of Disorder: Encounter between Conditionally Disordered CP12 and Glyceraldehyde-3-Phosphate Dehydrogenase.","date":"2018","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29501381","citation_count":18,"is_preprint":false},{"pmid":"18949657","id":"PMC_18949657","title":"Purification, molecular cloning, heterologous expression and characterization of pig CYP1A2.","date":"2008","source":"Xenobiotica; the fate of foreign compounds in biological systems","url":"https://pubmed.ncbi.nlm.nih.gov/18949657","citation_count":18,"is_preprint":false},{"pmid":"18573860","id":"PMC_18573860","title":"Characterization of substrate specificity of dog CYP1A2 using CYP1A2-deficient and wild-type dog liver microsomes.","date":"2008","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/18573860","citation_count":18,"is_preprint":false},{"pmid":"36176677","id":"PMC_36176677","title":"First in vivo analysis of the regulatory protein CP12 of the model cyanobacterium Synechocystis PCC 6803: Biotechnological implications.","date":"2022","source":"Frontiers in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/36176677","citation_count":16,"is_preprint":false},{"pmid":"21271977","id":"PMC_21271977","title":"Isolation and compositional analysis of a CP12-associated complex of calvin cycle enzymes from Nicotiana tabacum.","date":"2011","source":"Protein and peptide letters","url":"https://pubmed.ncbi.nlm.nih.gov/21271977","citation_count":16,"is_preprint":false},{"pmid":"36835057","id":"PMC_36835057","title":"Melatonin Activation by Cytochrome P450 Isozymes: How Does CYP1A2 Compare to CYP1A1?","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36835057","citation_count":16,"is_preprint":false},{"pmid":"19501084","id":"PMC_19501084","title":"Malaria downmodulates mRNA expression and catalytic activities of CYP1A2, 2E1 and 3A11 in mouse liver.","date":"2009","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19501084","citation_count":16,"is_preprint":false},{"pmid":"20541869","id":"PMC_20541869","title":"Induction of immune responses in mice by a DNA vaccine encoding Cryptosporidium parvum Cp12 and Cp21 and its effect against homologous oocyst challenge.","date":"2010","source":"Veterinary parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/20541869","citation_count":15,"is_preprint":false},{"pmid":"35872289","id":"PMC_35872289","title":"Psoralen and isopsoralen from Psoraleae Fructus aroused hepatotoxicity via induction of aryl hydrocarbon receptor-mediated CYP1A2 expression.","date":"2022","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35872289","citation_count":15,"is_preprint":false},{"pmid":"35316061","id":"PMC_35316061","title":"Metabolic Activation and Cytotoxicity of Fungicide Carbendazim Mediated by CYP1A2.","date":"2022","source":"Journal of agricultural and food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35316061","citation_count":15,"is_preprint":false},{"pmid":"30979496","id":"PMC_30979496","title":"CYP1A2 contributes to alcohol-induced abnormal lipid metabolism through the PTEN/AKT/SREBP-1c pathway.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30979496","citation_count":15,"is_preprint":false},{"pmid":"26022657","id":"PMC_26022657","title":"Functional characterization of 20 allelic variants of CYP1A2.","date":"2015","source":"Drug metabolism and pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/26022657","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":57814,"output_tokens":8098,"usd":0.147456,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17741,"output_tokens":6461,"usd":0.125115,"stage2_stop_reason":"end_turn"},"total_usd":0.272571,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1984,\n      \"finding\": \"Mouse cytochrome P3-450 (CYP1A2 ortholog) cDNA was fully sequenced, revealing a 513-residue protein with six cysteine residues; analysis of cysteinyl peptide-coding regions identified cysteine 456 as the likely thiolate ligand to the heme iron in the active site.\",\n      \"method\": \"cDNA cloning and sequencing; sequence homology analysis of cysteinyl peptide-coding regions\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — sequence-based identification of active-site cysteine, single study, no mutagenesis validation in this paper\",\n      \"pmids\": [\"6324134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"Mouse Cyp1a1 and Cyp1a2 (P1-450 and P3-450) structural genes were mapped to mouse chromosome 9 by Southern blot analysis of hamster-mouse somatic cell hybrids.\",\n      \"method\": \"Somatic cell hybrid Southern blot chromosome segregation analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct chromosomal mapping with 12 hybrid clones, clear segregation analysis\",\n      \"pmids\": [\"6328503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"CYP1A2 (cytochrome P3-450) cDNA encodes aflatoxin B1-4-hydroxylase activity, establishing CYP1A2 as the enzyme responsible for detoxification of AFB1 to aflatoxin M1; demonstrated by expression in mammalian cells via recombinant vaccinia virus.\",\n      \"method\": \"Recombinant vaccinia virus expression system; in vitro metabolic assay with AFB1 substrate\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct enzymatic reconstitution using cDNA-expressed protein, clear substrate-product demonstration\",\n      \"pmids\": [\"3137222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"CYP1A2 protein is highly variably expressed in human liver (>40-fold variation in mRNA); hepatic CYP1A2 mRNA levels significantly correlate with CYP1A2 protein levels by immunoblot. An abnormally spliced variant lacking exon 4 was identified in one individual with very low CYP1A2 protein, suggesting aberrant splicing as one mechanism of reduced expression.\",\n      \"method\": \"Quantitative PCR; immunoblot; cDNA cloning and sequencing; PCR splice variant analysis\",\n      \"journal\": \"Pharmacogenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (qPCR, immunoblot, sequencing) in single study; mechanistic link between splicing defect and low expression established\",\n      \"pmids\": [\"8287062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Mouse CYP1A2 preferentially catalyzes MROD (7-methoxyresorufin O-demethylase) activity, while CYP1A1 preferentially catalyzes benzo[a]pyrene hydroxylase and EROD activities; furafylline is a CYP1A2-selective inhibitor of MROD and EROD, whereas alpha-naphthoflavone equally inhibits AHH activity of CYP1A1 and CYP1A2.\",\n      \"method\": \"Vaccinia virus cDNA expression system; enzyme kinetics (kcat, Km); selective chemical inhibition; immunoblot\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted expressed enzyme with full kinetic characterization and isoform-specific inhibitors, replicated across microsomal and purified enzyme preparations\",\n      \"pmids\": [\"8274012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Human CYP1A2 (constitutively expressed in liver) is the primary enzyme responsible for N-hydroxylation and metabolic activation of heterocyclic amines IQ and MeIQx to mutagens; PhIP activation is shared with CYP1A1. This was established by correlation of CYP1A2 constitutive expression with activation rates in human and primate liver microsomes and by TCDD-induced CYP1A2 induction in marmoset with proportional increases in IQ and MeIQx activation.\",\n      \"method\": \"Human/primate liver microsomal incubations; Ames mutagenicity assay; correlation of CYP levels with activation rates; TCDD induction experiments\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple species, correlation and induction experiments, clear substrate-enzyme relationship established\",\n      \"pmids\": [\"8200083\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"CYP1A2-deficient (Cyp1a2−/−) mice develop normally and are fertile, but exhibit dramatically prolonged zoxazolamine-induced paralysis (a CYP1A2 substrate), demonstrating that CYP1A2 is required for in vivo metabolism of this substrate. Cyp1a2(+/−) heterozygotes show intermediate paralysis times.\",\n      \"method\": \"Homologous recombination knockout mouse; zoxazolamine paralysis test; Northern blot; histological examination\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with clear dose-dependent phenotypic readout, Northern blot confirmation of null expression\",\n      \"pmids\": [\"8643688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"CYP1A2 is the primary determinant of caffeine clearance in mice: Cyp1a2−/− mice show 7-fold longer caffeine half-life and 8-fold slower clearance compared to wild-type. Caffeine 3-demethylated metabolites (1-methylxanthine, 1-methylurate) are still formed in Cyp1a2−/− mice at 40% of wild-type levels, indicating additional P450s contribute.\",\n      \"method\": \"CYP1A2 knockout mouse pharmacokinetic study; blood caffeine measurement; urine metabolite analysis; liver function tests; Western blot for other P450s\",\n      \"journal\": \"Pharmacogenetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockout mouse with full pharmacokinetic characterization and metabolite profiling, confirmation that other P450s unaffected\",\n      \"pmids\": [\"8873215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CYP1A2 and CYP3A4 are both involved in demethylation of clozapine (CLZ) to desmethylclozapine (DCLZ); CYP3A4 is primarily responsible for N-oxidation of CLZ. CYP1A2 has lower Km and Vmax than CYP3A4 for demethylation, suggesting CYP1A2 is more important at low (therapeutic) CLZ concentrations. Demonstrated by chemical inhibitors (fluvoxamine, triacetyloleandomycin, ketoconazole), specific antibodies, and heterologous expression systems.\",\n      \"method\": \"Human liver microsomal incubations; chemical inhibitors; anti-CYP antibody inhibition; CYP expression systems; correlation analysis; enzyme kinetics (Km, Vmax)\",\n      \"journal\": \"British journal of clinical pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (inhibitors, antibodies, expressed enzymes, kinetics) in a single study\",\n      \"pmids\": [\"9384460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CYP1A2 protein is absent in human fetal and neonatal livers and shows delayed ontogenesis, with levels increasing from 1–3 months postnatal and reaching 50% of adult values at one year. Methoxyresorufin demethylase activity (CYP1A2-selective) follows this ontogenic profile. In early neonates, CYP3A mediates the low residual imipramine demethylation before CYP1A2 onset.\",\n      \"method\": \"Immunoblot with polyclonal anti-rat CYP1A antibody; enzymatic activity assays (methoxyresorufin demethylase, imipramine demethylation); human liver bank analysis across developmental stages\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — immunoblot plus enzyme activity, multiple developmental time points, clear ontogenic trajectory established\",\n      \"pmids\": [\"9490065\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CYP1A2 is not the sole enzyme responsible for 4-aminobiphenyl (4-ABP) N-hydroxylation in mice; in vivo hepatocarcinogenesis in Cyp1a2−/− mice showed no significant difference in overall tumor incidence compared to wild-type. In vitro studies confirmed another unidentified P450 contributes to 4-ABP N-hydroxylation in mice.\",\n      \"method\": \"Cyp1a2 knockout mouse neonatal bioassay; histological analysis of hepatic tumors and preneoplastic foci; in vitro microsomal N-hydroxylation assays with Cyp1a2−/− and wild-type microsomes\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockout mouse in vivo carcinogenesis study plus supporting in vitro enzyme assays; negative result for CYP1A2 as rate-limiting step is rigorously established\",\n      \"pmids\": [\"10469630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CYP1A2 is the major CYP isoform catalyzing lidocaine N-deethylation (MEGX formation) at low (therapeutically relevant) lidocaine concentrations (~60% inhibition by furafylline, >75% by anti-CYP1A1/2 antibodies), while CYP3A4 contribution increases at high lidocaine concentrations. CYP1A2 also almost exclusively catalyzes lidocaine 3-hydroxylation.\",\n      \"method\": \"Human liver microsomes; selective chemical inhibitors (furafylline, troleandomycin); immunoinhibition with anti-CYP antibodies; recombinant human CYP isoforms; enzyme kinetics\",\n      \"journal\": \"Drug metabolism and disposition: the biological fate of chemicals\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (chemical inhibition, immunoinhibition, recombinant enzymes) with concentration-dependent analysis\",\n      \"pmids\": [\"10901707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Both CYP1A2 and CYP2D6 catalyze propranolol 4-hydroxylation in human liver microsomes, with CYP1A2 contributing ~45% and CYP2D6 ~55% of total activity. Enzyme kinetics showed CYP1A2 Km of ~21 µM and CYP2D6 Km of ~8.5 µM for (S)-4-hydroxypropranolol formation.\",\n      \"method\": \"Human liver microsomes; recombinant CYP enzyme screening (11 isoforms); correlation analysis with CYP1A2 marker activity; selective chemical inhibitors (furafylline, quinidine); enzyme kinetics\",\n      \"journal\": \"The Journal of pharmacology and experimental therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — comprehensive enzyme screening, correlation, inhibition and kinetic methods in a single study\",\n      \"pmids\": [\"10945865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CYP1A2 is essential for hepatic uroporphyrin accumulation in hexachlorobenzene (HCBZ) and iron-induced murine uroporphyria: Cyp1a2−/− mice show no hepatic uroporphyrin accumulation even after additional HCBZ doses, while wild-type mice accumulate 300 nmol/g liver. HCBZ-induced uroporphyrinogen oxidation in microsomes was CYP1A2-dependent.\",\n      \"method\": \"Cyp1a2 knockout mouse; hepatic uroporphyrin measurement; Western immunoblotting for CYP proteins; microsomal uroporphyrinogen oxidation assay\",\n      \"journal\": \"Toxicology and applied pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockout mouse with quantitative biochemical endpoints, Western blot confirmation, combined inducer and precursor treatments\",\n      \"pmids\": [\"10631128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"A heterozygous point mutation in the donor splice site of intron 6 (3534G>A) of CYP1A2 was identified as the likely cause of very low CYP1A2 activity (and high clozapine plasma concentrations) in a patient; this mutation is predicted to cause abnormal RNA splicing and a truncated nonfunctional enzyme. This is the first reported splice-site mutation in CYP1A2.\",\n      \"method\": \"Direct sequencing of all 7 exons, exon-intron boundaries, and 5'-flanking region; caffeine phenotyping; population screen of 100 Caucasians\",\n      \"journal\": \"British journal of clinical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — sequencing identifies mechanistic defect (splice site mutation) with phenotypic correlation; functional validation of truncated protein not directly shown\",\n      \"pmids\": [\"12919186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CYP1A2 decreases microsomal reactive oxygen production (H2O2) possibly by acting as an 'electron sink,' reducing CYP2E1- and CYP1A1-mediated oxidative stress. Cyp1a2−/− mice showed significantly higher NADPH-dependent H2O2 production in microsomes compared to wild-type, and CYP1A2 inhibitor furafylline exacerbated H2O2 production proportional to degree of CYP1A2 inhibition.\",\n      \"method\": \"Cyp1a2 knockout mouse liver microsomes; NADPH-dependent H2O2 measurement; TCDD induction; furafylline inhibition; TBARS assay; membrane polarization anisotropy\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockout and chemical inhibitor approaches with multiple readouts (H2O2, TBARS, membrane polarization) in a single study\",\n      \"pmids\": [\"14980704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CYP1A2 mediates pentoxifylline (PTX) metabolism in mice: Cyp1a2 knockout mice have significantly elevated serum PTX levels compared to wild-type at 20 minutes post-injection. Furafylline (selective CYP1A2 inhibitor) inhibits PTX metabolism in murine hepatic microsomes, and ciprofloxacin inhibits PTX metabolism without downregulating CYP1A2 protein.\",\n      \"method\": \"Cyp1a2 knockout mouse; furafylline inhibition; in vitro hepatic microsomal incubation; serum PTX measurement; Western blot for CYP1A2 and CYP2E1\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockout mouse and selective inhibitor both confirm CYP1A2 role; drug interaction mechanism clarified\",\n      \"pmids\": [\"15194011\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Pyrene-induced CYP1A2 expression (protein, mRNA, and EROD/pyrene 1-hydroxylation activities) occurs in both AhR(+/+) and AhR(−/−) mice, demonstrating that pyrene-induced CYP1A2 is regulated by constitutive androstane receptor (CAR) rather than AhR. Pyrene simultaneously induced CAR and its target CYP2B10 in both genotypes.\",\n      \"method\": \"AhR knockout and wild-type mouse in vivo exposure; hepatic protein and mRNA expression by Western blot and RT-PCR; enzyme activity assays (EROD, MROD); CAR and CYP2B10 expression analysis\",\n      \"journal\": \"Toxicology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with orthogonal mRNA, protein, and activity measurements; clearly establishes CAR not AhR as regulator for pyrene induction\",\n      \"pmids\": [\"17618724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Omeprazole induces both CYP1A1 and CYP1A2 transcription through a common regulatory region containing multiple AhR-binding motifs (nucleotides −464 to −1829 of human CYP1A1), identical to the region for beta-naphthoflavone and 3-methylcholanthrene induction, but omeprazole activates both CYP1A1 and CYP1A2 to similar extents while BNF and 3MC prefer CYP1A1.\",\n      \"method\": \"Transient transfection of dual reporter gene constructs with deletion constructs in human hepatoma cells; AhR-dependence confirmed\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reporter gene assays with multiple deletion constructs identifying specific regulatory region; single lab but orthogonal constructs\",\n      \"pmids\": [\"18502397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Mouse Cyp1a1 and Cyp1a2 genes are arranged in head-to-head orientation separated by ~13.9 kb; eight consensus dioxin responsive elements (DREs) are present in this junction, with seven located within 1.4 kb upstream of Cyp1a1 but no conserved DREs in the proximal Cyp1a2 upstream region. This genomic architecture is conserved across human, mouse, cattle, dog, and rat.\",\n      \"method\": \"Comparative genomic DNA sequence analysis; identification of DRE motifs; evolutionary conservation analysis across mammalian genomes\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — comprehensive genomic sequence analysis across multiple species; mechanistic implication for differential AhR-mediated regulation; no functional reporter validation in this paper\",\n      \"pmids\": [\"19026991\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CYP1A2 gene expression in human liver is regulated by DNA methylation: extent of methylation of a CpG island near the translation start site inversely correlates with hepatic CYP1A2 mRNA levels. Methylation of two core CpG sites is strongly associated with CYP1A2 mRNA levels and allele-specific expression phenotype. CYP1A2 expression in hepatoma cells was induced by the demethylating agent 5-aza-2'-deoxycytidine.\",\n      \"method\": \"65 human liver samples; allele-specific expression analysis; CpG island methylation analysis; 5-aza-2'-deoxycytidine treatment of hepatoma cells; correlation analysis\",\n      \"journal\": \"The pharmacogenomics journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — methylation-expression correlation confirmed by pharmacological demethylation in cell line; multiple CpG sites analyzed in large human liver panel\",\n      \"pmids\": [\"19274061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Functional characterization of 20 CYP1A2 amino acid substitution variants showed that CYP1A2*4, *6, *8, *15, *16, and *21 are completely inactive toward both phenacetin and 7-ethoxyresorufin. CYP1A2*11 shows markedly reduced activity with substrate-dependent changes in Km. CYP1A2*14 and *20 exhibit increased enzymatic activity compared to wild-type CYP1A2*1.\",\n      \"method\": \"Heterologous expression in COS-7 cells; enzyme kinetics (Km, Vmax) with two substrates (phenacetin O-deethylation, 7-ethoxyresorufin O-deethylation)\",\n      \"journal\": \"Drug metabolism and pharmacokinetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted expressed variant proteins with full enzyme kinetics using two substrates; comprehensive allele survey\",\n      \"pmids\": [\"26022657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Using mice humanized for human CYP1A1/CYP1A2 combined with Cyp1a1/Cyp1a2 double knockout mice, CYP1A2 was shown to be constitutively expressed in the liver while both proteins are highly inducible by TCDD in liver, lung, kidney, and small intestine. Both CYP1A1 and CYP1A2 contribute to hepatic metabolism of 7-methoxy and 7-ethoxyresorufin; differential inhibition by quinidine allows quantitative partitioning of their respective contributions.\",\n      \"method\": \"Humanized CYP1A1/1A2 mice; Cyp1a1/Cyp1a2 knockout mice; microsomal enzyme kinetics; selective inhibition by quinidine; TCDD induction; tissue expression profiling\",\n      \"journal\": \"Drug metabolism and disposition: the biological fate of chemicals\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — humanized and knockout mouse models combined with enzyme kinetic modeling; multiple tissues and substrates\",\n      \"pmids\": [\"31147315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CYP1A2 acts as a tumor suppressor in hepatocellular carcinoma by directly binding to HIF-1α (confirmed by Co-immunoprecipitation), inducing ubiquitin-mediated degradation of HIF-1α, thereby inhibiting HIF-1α-mediated transcription of MET and reducing HGF/MET signaling pathway activation and MMP expression.\",\n      \"method\": \"Co-immunoprecipitation; Western blot; overexpression and knockdown in HCC cell lines; in vivo xenograft; Western blot; qRT-PCR; immunohistochemistry\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP establishes binding; multiple functional assays in vitro and in vivo; single lab with two orthogonal methods but ubiquitination mechanism not directly reconstituted\",\n      \"pmids\": [\"33500715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Kupffer cell-derived proinflammatory cytokines (TNF-α and IL-1β) suppress hepatocyte CYP1A2 expression in sepsis via downregulation of AhR/ARNT; anti-TNF-α and anti-IL-1β antibodies attenuated CYP1A2 downregulation in co-culture. LPS alone did not suppress CYP1A2 without direct Kupffer cell–hepatocyte contact.\",\n      \"method\": \"Primary Kupffer cell and hepatocyte co-culture (with and without transwells); anti-cytokine antibodies; CLP rat sepsis model; curcumin pretreatment; CYP1A2, AhR, ARNT expression analysis\",\n      \"journal\": \"International journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro co-culture and in vivo sepsis model with antibody blockade; pathway (AhR/ARNT) identified mechanistically\",\n      \"pmids\": [\"16820944\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CYP1A2 contributes to alcohol-induced abnormal lipid metabolism through the PTEN/AKT/SREBP-1c pathway: siRNA-mediated knockdown or fluvoxamine inhibition of CYP1A2 in L02 cells reduced ethanol-induced ALT, triglycerides, and SREBP-1c expression, while modulation of PTEN/AKT upstream of SREBP-1c confirmed pathway involvement.\",\n      \"method\": \"siRNA knockdown; pharmacological inhibition with fluvoxamine; PTEN siRNA; bpv (PTEN inhibitor); Western blot for PTEN, p-AKT, SREBP-1c; ALT and triglyceride measurement in cell culture\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — loss-of-function with siRNA and chemical inhibitor plus pathway validation by PTEN manipulation; single lab, in vitro only\",\n      \"pmids\": [\"30979496\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CYP1A2 is induced by psoralen and isopsoralen via AhR-mediated transcriptional activation: both compounds bind AhR and activate its translocation from cytoplasm to nucleus, leading to transcriptional upregulation of CYP1A2, which mediates their hepatotoxicity. Shown in vitro and in vivo by AhR binding, nucleocytoplasmic shuttling, and CYP1A2 activity assays.\",\n      \"method\": \"HepG2 cells and mouse in vivo; cellular thermal shift assay; molecular docking; immunofluorescence (AhR translocation); CYP1A2 mRNA, protein, and phenacetin metabolism assays\",\n      \"journal\": \"Journal of ethnopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — thermal shift assay and nuclear translocation imaging establish AhR binding mechanism; CYP1A2 activity and mRNA confirmed in vivo and in vitro\",\n      \"pmids\": [\"35872289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CYP1A2 is the major enzyme responsible for metabolic activation (N-hydroxylation/oxidation) of the fungicide carbendazim to a reactive electrophilic metabolite that forms glutathione conjugates and protein adducts, contributing to hepatotoxicity. Biliary and urinary conjugate metabolites were detected in rats, and protein adduction in primary hepatocytes correlated with cytotoxicity.\",\n      \"method\": \"Human and rat liver microsomal incubation; GSH and NAC trapping; LC-MS/MS metabolite identification; in vivo rat biliary/urinary metabolite detection; protein adduction in rat primary hepatocytes\",\n      \"journal\": \"Journal of agricultural and food chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with trapping and MS confirmation; in vivo rat metabolites; single lab\",\n      \"pmids\": [\"35316061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Molecular dynamics and quantum chemical calculations on CYP1A2 crystal structure with docked melatonin predict that CYP1A2 catalyzes melatonin 6-hydroxylation (aromatic hydroxylation) and O-demethylation (forming N-acetylserotonin) via the heme-iron oxo intermediate; calculated barrier heights are consistent with experimental product distributions and explain species differences with CYP1A1.\",\n      \"method\": \"Molecular dynamics simulation (up to 1 µs); density functional theory (DFT) quantum chemical cluster models; starting from crystal structure coordinates; substrate docking\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — computational-only study (MD + QM), no experimental validation of mechanism in this paper\",\n      \"pmids\": [\"36835057\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CYP1A2 is a predominantly hepatic cytochrome P450 enzyme (constitutively expressed, absent in fetal/neonatal liver) that uses a heme-iron active site (with cysteine 456 as the thiolate ligand) to catalyze oxidative metabolism of diverse substrates including caffeine, theophylline, clozapine, lidocaine, propranolol, heterocyclic amines, and aflatoxin B1; its transcription is induced through AhR/ARNT-dependent binding to dioxin responsive elements (shared with CYP1A1 in a head-to-head genomic locus) by ligands including TCDD, 3-methylcholanthrene, and omeprazole, and is also regulated by DNA methylation of a proximal CpG island, suppressed in sepsis via Kupffer cell-derived cytokines (TNF-α/IL-1β) reducing AhR/ARNT, and induced by CAR (not AhR) in response to pyrene; beyond drug metabolism, CYP1A2 plays roles in reducing microsomal reactive oxygen production (acting as an electron sink to limit CYP2E1/CYP1A1-mediated H2O2), is essential for porphyrinogen oxidation leading to uroporphyria, suppresses hepatocellular carcinoma by binding HIF-1α and promoting its ubiquitin-mediated degradation to antagonize HGF/MET signaling, and participates in alcohol-induced lipid dysregulation through the PTEN/AKT/SREBP-1c pathway.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CYP1A2 is a constitutively expressed hepatic cytochrome P450 monooxygenase that uses a heme-iron active site, with cysteine 456 serving as the thiolate ligand, to catalyze oxidative metabolism of structurally diverse xenobiotics and drugs [#0, #4]. Its substrate spectrum established by reconstituted-enzyme and knockout-mouse studies includes aflatoxin B1 (4-hydroxylation to aflatoxin M1) [#2], heterocyclic amines IQ and MeIQx (N-hydroxylation to mutagens) [#5], caffeine, zoxazolamine, clozapine, lidocaine, propranolol, and pentoxifylline [#6, #7, #8, #11, #12, #16]; for several of these CYP1A2 dominates at low therapeutic concentrations while other P450s (CYP3A4, CYP2D6) contribute at higher concentrations [#8, #11, #12]. CYP1A2 is the selective catalyst of methoxyresorufin O-demethylation, distinguishing it from CYP1A1 [#4, #22]. Beyond metabolism, CYP1A2 limits microsomal reactive oxygen production by acting as an electron sink that suppresses CYP2E1/CYP1A1-mediated H2O2 generation [#15], is required for hepatic uroporphyrin accumulation through uroporphyrinogen oxidation in murine uroporphyria [#13], and acts as a tumor suppressor in hepatocellular carcinoma by binding HIF-1\\u03b1 and promoting its ubiquitin-mediated degradation to antagonize HGF/MET signaling [#23]. CYP1A2 transcription is induced through AhR-dependent binding to dioxin responsive elements shared with CYP1A1 at a conserved head-to-head genomic locus, by ligands including 3-methylcholanthrene, beta-naphthoflavone, omeprazole, and psoralen/isopsoralen [#18, #19, #26], but pyrene-induced expression is mediated by the constitutive androstane receptor rather than AhR [#17]. Expression is further controlled by DNA methylation of a proximal CpG island [#20] and is suppressed in sepsis via Kupffer cell-derived TNF-\\u03b1/IL-1\\u03b2 acting through downregulation of AhR/ARNT [#24]. The enzyme is absent in fetal and neonatal liver with delayed postnatal ontogenesis [#9], and human expression is highly variable, partly through splice-site mutations and amino acid variants that abolish or alter activity [#3, #14, #21].\",\n  \"teleology\": [\n    {\n      \"year\": 1984,\n      \"claim\": \"Established the primary structure and the heme-iron coordination chemistry of the CYP1A2 ortholog, identifying cysteine 456 as the active-site thiolate ligand and mapping the gene physically next to CYP1A1.\",\n      \"evidence\": \"cDNA cloning/sequencing and cysteinyl peptide analysis plus somatic cell hybrid chromosome mapping in mouse\",\n      \"pmids\": [\"6324134\", \"6328503\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cysteine 456 thiolate assignment was sequence-based, not validated by mutagenesis\", \"No catalytic activity demonstrated at this stage\"]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Resolved which enzyme detoxifies aflatoxin B1 by showing CYP1A2 itself catalyzes AFB1 4-hydroxylation, establishing direct enzyme-substrate function.\",\n      \"evidence\": \"Recombinant vaccinia virus expression of CYP1A2 cDNA with in vitro AFB1 metabolic assay\",\n      \"pmids\": [\"3137222\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address relative contribution versus other P450s in vivo\", \"No structural basis for substrate selectivity\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Defined the catalytic fingerprint that distinguishes CYP1A2 from CYP1A1 and provided isoform-selective chemical tools (furafylline), enabling all later attribution of activities to CYP1A2.\",\n      \"evidence\": \"Vaccinia cDNA expression with enzyme kinetics and selective inhibition (MROD vs EROD/BaP hydroxylase)\",\n      \"pmids\": [\"8274012\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Inhibitor selectivity is partial (alpha-naphthoflavone inhibits both isoforms)\", \"Mouse enzyme; human equivalence assumed\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Linked CYP1A2's constitutive hepatic expression to procarcinogen activation, showing it is the primary enzyme bioactivating heterocyclic amines IQ and MeIQx to mutagens.\",\n      \"evidence\": \"Human/primate liver microsomes, Ames mutagenicity assay, CYP-level correlation, and TCDD induction in marmoset\",\n      \"pmids\": [\"8200083\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PhIP activation shared with CYP1A1, not CYP1A2-specific\", \"Correlative attribution rather than purified enzyme for all activities\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Established in vivo physiological substrate dependence using genetic knockouts, proving CYP1A2 is rate-determining for zoxazolamine and caffeine clearance while other P450s partially compensate.\",\n      \"evidence\": \"Cyp1a2\\u2212/\\u2212 knockout mice with paralysis test and pharmacokinetic/metabolite profiling\",\n      \"pmids\": [\"8643688\", \"8873215\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of compensating caffeine-metabolizing P450s not determined\", \"Mouse pharmacokinetics may differ from human\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Clarified clinically relevant drug metabolism by showing CYP1A2 dominates clozapine demethylation at therapeutic concentrations through its low Km, with CYP3A4 dominating at higher concentrations.\",\n      \"evidence\": \"Human liver microsomes with chemical inhibitors, anti-CYP antibodies, expression systems, and kinetics\",\n      \"pmids\": [\"9384460\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative in vivo contribution depends on hepatic enzyme abundance not measured here\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Defined the developmental trajectory of CYP1A2, establishing its absence in fetal/neonatal liver and delayed postnatal onset, explaining pediatric drug-handling differences.\",\n      \"evidence\": \"Immunoblot and MROD/imipramine activity assays across a developmental human liver bank\",\n      \"pmids\": [\"9490065\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular trigger of postnatal induction not identified\", \"Antibody is anti-rat CYP1A, cross-reactivity caveats\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Extended the CYP1A2 substrate map to lidocaine and propranolol, quantifying its concentration-dependent and fractional contributions relative to CYP3A4 and CYP2D6.\",\n      \"evidence\": \"Human liver microsomes, recombinant isoform screening, selective inhibition, and kinetics\",\n      \"pmids\": [\"10901707\", \"10945865\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo metabolic partitioning in humans not directly measured\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Revealed a non-xenobiotic physiological role: CYP1A2 is required for hepatic uroporphyrinogen oxidation and uroporphyria, linking the enzyme to porphyrin metabolism.\",\n      \"evidence\": \"Cyp1a2\\u2212/\\u2212 mice with HCBZ/iron treatment, uroporphyrin quantification, and microsomal oxidation assay\",\n      \"pmids\": [\"10631128\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Catalytic mechanism of uroporphyrinogen oxidation not reconstituted\", \"Human relevance not directly shown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Tested but did not confirm CYP1A2 as a rate-limiting carcinogen activator in vivo, showing it is not the sole enzyme for 4-aminobiphenyl N-hydroxylation in mice.\",\n      \"evidence\": \"Cyp1a2\\u2212/\\u2212 neonatal hepatocarcinogenesis bioassay plus in vitro microsomal N-hydroxylation\",\n      \"pmids\": [\"10469630\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the alternative N-hydroxylating P450 unknown\", \"Negative result; may not extrapolate to humans\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified a protective antioxidant function whereby CYP1A2 acts as an electron sink limiting CYP2E1/CYP1A1-mediated microsomal H2O2 production.\",\n      \"evidence\": \"Cyp1a2\\u2212/\\u2212 microsomes, NADPH-dependent H2O2 and TBARS assays, furafylline inhibition\",\n      \"pmids\": [\"14980704\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of electron-sink behavior not biochemically resolved\", \"In vivo physiological significance not quantified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined an inflammatory suppression mechanism, showing Kupffer cell TNF-\\u03b1/IL-1\\u03b2 downregulate hepatocyte CYP1A2 via AhR/ARNT during sepsis, requiring direct cell contact.\",\n      \"evidence\": \"Kupffer cell\\u2013hepatocyte co-culture with transwells and anti-cytokine antibodies plus CLP rat sepsis model\",\n      \"pmids\": [\"16820944\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Contact-dependent signal beyond cytokines not identified\", \"AhR/ARNT downregulation mechanism not resolved at transcriptional level\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Distinguished receptor-specific induction routes, demonstrating pyrene induces CYP1A2 through CAR rather than AhR.\",\n      \"evidence\": \"AhR knockout vs wild-type mice with mRNA, protein, and EROD/MROD activity plus CAR/CYP2B10 readouts\",\n      \"pmids\": [\"17618724\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct CAR binding to CYP1A2 regulatory elements not shown\", \"Generality across other CAR ligands untested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Mapped the cis-regulatory architecture of AhR-mediated induction, identifying a shared CYP1A1/CYP1A2 regulatory region with dioxin responsive elements and a conserved head-to-head genomic locus.\",\n      \"evidence\": \"Dual reporter deletion constructs in hepatoma cells (omeprazole/BNF/3MC) and comparative genomic DRE analysis across mammals\",\n      \"pmids\": [\"18502397\", \"19026991\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Lack of proximal CYP1A2 DREs leaves the precise enhancer driving CYP1A2 unresolved\", \"Genomic DRE analysis lacks functional reporter validation\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Established epigenetic control of CYP1A2, showing CpG island methylation inversely controls hepatic expression and underlies allele-specific expression variability.\",\n      \"evidence\": \"Methylation-expression correlation in 65 human livers and 5-aza-2'-deoxycytidine induction in hepatoma cells\",\n      \"pmids\": [\"19274061\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcription factors recruited to the methylated region not identified\", \"Causal direction at single CpG sites inferred from correlation plus pharmacology\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Provided a genetic mechanism for interindividual deficiency, identifying splice-site and abnormal-splicing variants causing low CYP1A2 activity and altered drug response.\",\n      \"evidence\": \"Direct sequencing with caffeine phenotyping and population screening; earlier exon-4 deletion variant\",\n      \"pmids\": [\"12919186\", \"8287062\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional translation/protein products of truncated transcripts not validated\", \"Single-patient observations require population confirmation\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Systematically defined the functional consequences of coding variants, identifying null, reduced-function, and gain-of-function CYP1A2 alleles.\",\n      \"evidence\": \"Heterologous expression of 20 variants in COS-7 cells with kinetics on two substrates\",\n      \"pmids\": [\"26022657\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo pharmacokinetic consequences of variants not measured\", \"Substrate-dependence implies activity calls may vary for other substrates\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Quantitatively partitioned hepatic CYP1A1 vs CYP1A2 contributions and confirmed constitutive hepatic CYP1A2 with broad inducibility using humanized and double-knockout mice.\",\n      \"evidence\": \"Humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 knockout mice with microsomal kinetics, quinidine inhibition, and TCDD tissue profiling\",\n      \"pmids\": [\"31147315\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Humanized model may not fully recapitulate human regulatory context\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Connected CYP1A2 to lipid pathophysiology, implicating it in alcohol-induced lipid dysregulation through the PTEN/AKT/SREBP-1c pathway.\",\n      \"evidence\": \"siRNA knockdown and fluvoxamine inhibition in L02 cells with PTEN manipulation and Western blots\",\n      \"pmids\": [\"30979496\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vitro single cell line only; no in vivo confirmation\", \"Direct enzymatic link between CYP1A2 catalysis and PTEN/AKT not established\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined a non-catalytic tumor-suppressor function: CYP1A2 binds HIF-1\\u03b1 and drives its ubiquitin-mediated degradation to suppress HGF/MET signaling in hepatocellular carcinoma.\",\n      \"evidence\": \"Co-immunoprecipitation, overexpression/knockdown in HCC cell lines, and in vivo xenografts\",\n      \"pmids\": [\"33500715\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitination mechanism not reconstituted; E3 ligase not identified\", \"Co-IP without reciprocal structural validation of the CYP1A2\\u2013HIF-1\\u03b1 interface\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended induction and bioactivation roles to herbal/agricultural toxicants, showing AhR-mediated induction by psoralen/isopsoralen and CYP1A2-dependent bioactivation of carbendazim to reactive adduct-forming metabolites.\",\n      \"evidence\": \"Thermal shift, docking, AhR translocation imaging, microsomal trapping/LC-MS, and in vivo rat metabolite detection\",\n      \"pmids\": [\"35872289\", \"35316061\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct AhR-DRE engagement for psoralen not demonstrated by ChIP\", \"Single-lab bioactivation studies for carbendazim\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Provided a computational mechanistic model of CYP1A2 catalysis on melatonin, predicting 6-hydroxylation and O-demethylation via the heme-iron oxo intermediate.\",\n      \"evidence\": \"Molecular dynamics and DFT quantum chemical calculations on the CYP1A2 crystal structure with docked melatonin\",\n      \"pmids\": [\"36835057\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Computational-only; no experimental validation in this study\", \"Predicted product distribution not biochemically confirmed here\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CYP1A2's catalytic monooxygenase function mechanistically integrates with its non-catalytic regulatory roles (HIF-1\\u03b1 degradation, electron-sink antioxidant activity, lipid signaling) remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural definition of the CYP1A2\\u2013HIF-1\\u03b1 interaction\", \"E3 ligase mediating HIF-1\\u03b1 degradation unidentified\", \"Biochemical basis of electron-sink behavior not resolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [2, 4, 5, 11, 12, 15]},\n      {\"term_id\": \"GO:0005506\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [15, 22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9748784\", \"supporting_discovery_ids\": [7, 8, 11, 12]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [2, 13, 25]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [23, 27]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"AHR\",\n      \"ARNT\",\n      \"HIF1A\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}